UnitedHealth Group (UNH) moved back into focus after a sharp reaction to several catalysts, including strong Q1 2026 results, multiple analyst upgrades and investor interest around higher Medicare Advantage payment rates.

The recent 7.0% 30 day share price return and 44.0% 90 day share price return suggest momentum has picked up as investors react to Q1 2026 results, higher Medicare Advantage rates and dividend growth, even though the 3 year total shareholder return is still down 12.45%.

If UnitedHealth’s recent move has you thinking about where else health and AI could intersect, it is worth scanning opportunities in 39 healthcare AI stocks

With the stock up strongly over the past quarter, trading near the average analyst price target of US$407 and flagged as intrinsically discounted by some models, you have to ask: is there still an entry point here, or is future growth already priced in?

Most Popular Narrative: 2.9% Overvalued

The most followed narrative on UnitedHealth Group pegs fair value at $395, slightly below the last close at $406.57, which suggests a modest premium being paid for the stock right now.

Our thesis centers on the fact that the market is discounting the massive value of Optum (Insight, Health, and Rx). While the insurance arm (UnitedHealthcare) is undergoing a painful but necessary "right-sizing", shedding ~1.4M members to prioritize margins, Optum continues to scale. By buying UNH at a 13x-15x Forward P/E, investors are essentially acquiring the world’s most powerful healthcare data ecosystem at a "legacy utility" multiple.

Read the complete narrative. Read the complete narrative.

The fair value hinges on how far Optum’s data and services business can stretch margins while the insurance book is reshaped. The core assumptions quietly link earnings growth, margin repair and capital returns into one tight equation. If you want to see exactly how those moving parts translate into that fair value range, the full narrative sets out the playbook in detail.

Result: Fair Value of $395 (OVERVALUED)

However, you still need to watch for tighter Medicare regulation or slower progress on Optum’s profitability, as either of these could challenge this overvaluation thesis.

Another View: Cash Flows Point the Other Way

While the most popular narrative sees UnitedHealth Group as 2.9% overvalued at a fair value of $395, our DCF model presents a different picture. Based on projected cash flows, the stock appears undervalued, with a fair value estimate of $905.35 versus the current $406.57.

That gap is large enough to raise a real question for you as an investor: is the market overpaying relative to near term earnings, or underpaying for longer term cash generation potential?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out UnitedHealth Group for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 47 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Given the mix of optimism and concern in these narratives, it makes sense to move quickly, test the assumptions against your own view, and see how they stack up against the 3 key rewards and 2 important warning signs.

Looking for more investment ideas?

If UnitedHealth has sharpened your focus, do not stop here. Widen your search now and let data driven screeners surface stocks you might otherwise overlook.

• Target dependable cash generators by scanning 47 high quality undervalued stocks, which combine quality fundamentals with prices that may not fully reflect their financial strength.
• Prioritise resilience first and stress test your comfort with risk using 63 resilient stocks with low risk scores, which score well on balance sheet and volatility metrics.
• Get ahead of the crowd by checking screener containing 21 high quality undiscovered gems, which pair solid fundamentals with limited current attention from the broader market.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.